Valentina Tarasova, MD
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1902039027
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,102 of the $2,657 with a category attached, or 79.1%. 4 manufacturers reported payments, led by Exelixis Inc. at 51.0% of the total. Reporting peaked in 2019 at $1,354 and has fallen 87.5% since, to $169 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 14 payments — averaging $189.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$1K
- Eli Lilly$1K
- Esteve Pharmaceuticals LLC$169
- Recordati_rare_diseases_inc.$60
Across 13 payments — averaging $2840.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$35K
- Eli Lilly$1K
What the payments were for
- Travel & lodging$2,10279%
- Food & beverage$55521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 9 | $1,354 |
| Eli Lilly | 3 | $1,074 |
| Esteve Pharmaceuticals LLC | 1 | $169 |
| Recordati_rare_diseases_inc. | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lysodren$169
How this compares
$2,657 in reported general payments places this provider in the 45th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LysodrenMitotane | 20 | $39,222 |
| SynthroidLevothyroxine Sodium | 59 | $6,173 |
| Hydrocortisone | 50 | $3,628 |
| Levothyroxine Sodium | 166 | $1,887 |
| Alendronate Sodium | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Tampa
- Manuel Sainz de la PenaTampa$247K
- Yuvraj KumbkarniTampa$189K
- Andrew HenryTampa$173K
- Bryan McIverTampa$66K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.